Isoxazoline Drugs Market Size, Share & Trends Analysis Report By Product Type (Fluralaner, Sarolaner, Lotilaner, Afoxolaner), By Pet Type (Dogs, Cats) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Isoxazoline Drugs Market Size

The global isoxazoline drugs market size was valued at USD 6.1 billion in 2025 and is projected to grow from USD 6.99 billion in 2026 to USD 20.80 billion by 2034, registering a CAGR of 14.6% during the forecast period from 2026 to 2034. Asia Pacific dominated the isoxazoline drugs market with a market share of 38.4% in 2025.

Isoxazoline class of drugs are oral insecticides that received a license for ectoparasite treatment in companion animals such as dogs and cats. These drugs were first launched in 2013 as veterinary drugs against ticks and fleas in dogs. However, several studies have shown their efficiency against other veterinary and agricultural parasites. FDA-approved products in the isoxazoline drugs class are Bravecto, Credlio, Nexgard, and Simparica.

The US FDA approves these drugs for tick and flea infestation. Some of them are also approved for treating gastrointestinal parasite infections and controlling ear mites. These drugs are ingested or applied topically. Most active ingredients were introduced for crop protection and later for companion animals.

Innovations on the existing drugs for new indications in oral and topical formulations and growing awareness for ectoparasites prevention and control of fleas and ticks, are likely to augment the market growth. The market is segmented into product type, pet type, and region.

Segmental Analysis

The global isoxazoline drugs market is segmented into fluralaner, sarolaner, lotilaner, and afoxolaner based on product type. Afoxolaner type of drug had higher sales than the other drugs available in the market and held the largest market share in 2021.

Request Customizationto receive a tailored report.

Based on pet type, the market is categorized into dogs and cats. The adoption rate of dogs and cats surged during 2020–2021. According to a survey conducted by the Humane Society of the United States, nearly 45% of the household in the US owns at least one dog. In 2021, the dogs' segment acquired the majority of the share and is expected to grow at a CAGR of 18.11% during the forecast period.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America acquired the largest share of the isoxazoline drugs market in 2021 and a CAGR of 16.8% during the forecast period. The highest number of drug approvals and a higher adoption rate are among the major factors contributing to the growth of the market.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia-Pacific is anticipated to hold the highest market share in the isoxazoline drugs market. The rising adoption rate in countries such as India and China and growing awareness of pet care among the population are anticipated to propel the market during the projected period. Growing expenditure for pet care in India is likely to provide booming opportunities. According to the Indian Federation of Animal Health Companies, "the Indian animal healthcare market is estimated to be around Rs. 5,500 crores (USD 770 million) (2020).”

Approximately 5% of the animal healthcare expenditure is spent on companion animals. The lack of isoxazoline manufacturers in these regions also presents an opportunity for well-established players. Moreover, companies are targeting to get the approval of their drugs in India and China. Such factors are anticipated to provide great opportunities to the manufacturers for expanding their reach in these developing countries.

List of Key and Emerging Players in Isoxazoline Drugs Market